Basal cell carcinoma - Mate Pukupuku Pūtau Basal
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Ko te mate kiri o te ihu o te tangata kaumātua ka kitea he Mate Pukupuku Pūtau Basal (Basal cell carcinoma). Ko te ihu te waahi ka kitea mo tenei momo mate pukupuku kiri.
Mate Pukupuku Pūtau Basal (Basal cell carcinoma) ka puta mai he taitapa kopikopiko me nga whewhe.
Mate Pukupuku Pūtau Basal (Basal cell carcinoma) ka pohehe he kiritona.
References
Ko Basal cell carcinoma (BCC) te momo tino mate pukupuku kiri. Ko te whiti o te ra te take matua. Tata ki te katoa o nga keehi BCC e whakaatu ana i te kaha o te Hedgehog tohu i roto i te tātaritanga ngota. He rereke nga maimoatanga e waatea ana me te whiriwhiri i runga i te tupono ka hoki mai ano, te hiranga o te tiaki kiko, te hiahia o te manawanui, me te nui o te mate.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Ko te Basal cell carcinomas te momo mate pukupuku kiri e tino kitea ana i roto i nga pakeke kiri-tika te pakeke 50 neke atu. Kei te piki haere a raatau nama puta noa i te ao, ko te nuinga na te maaramatanga o te ra. Ko etahi o nga ahuatanga ira ka kaha te tangata ki te whakawhanake i enei mate pukupuku i te tamarikitanga. Basal cell carcinomas he rerekee te taumahatanga, mai i nga reinga papapapa, nodular ranei ka ngawari ki te rongoa ki nga mea whanui ake e hiahia ana ki te korerorero i roto i nga roopu rongoa motuhake. Ko te matapaetanga ka whakawhirinaki ki te hokinga mai o te mate pukupuku, i tona kaha ki te tukino i nga kiko tata. Ko te pokanga te maimoatanga paerewa mo te nuinga o nga keehi, me te whakarite kia tika te tango me te iti o te tupono ka hoki mai ano. Ka taea e nga tikanga whakaeke iti ake te rongoa i nga whiu papa.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ko te maimoatanga tuatahi mo te BCC he pokanga. Mo te BCC morearea nui, ka hoki mai ano ranei, ina koa i nga waahi tino nui, ka tūtohuhia he pokanga micrographically controlled. Ko nga turoro me te BCC iti morearea ka whakaaro pea ki nga maimoatanga kaupapa, ki nga tikanga kino ranei. He pai te mahi whakamaarama Photodynamic mo nga BCC nodular papapapa me te iti morearea. Mo te BCC matatau o te rohe, he metastatic ranei, ka tūtohuhia nga aukati Hedgehog (vismodegib, sonidegib) . Mena kei te haere tonu te mate, te kare ranei ki te aukati Hedgehog, ka taea te whakaaro ki te whakamaarama mate mate me te anti-PD1 antibody (cemiplimab) . He pai te mahi irirangi mo nga turoro kaore e taea te mahi pokanga, ina koa nga turoro pakeke. Ka taea te whakaaro te whakamaarama hiko ki te kore te pokanga, te whakamaarama irirangi ranei.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Ko nga mea morearea ko te rongo ki te rama ultraviolet, te whakamaarama iraruke, te rongo mo te wa roa ki te arsenic me te ngoikore o te mahi a te punaha mate (hei tauira, te whakawhitinga okana). He tino kino te pa ki te rama UV i te wa e tamariki ana.
I muri i te taatai ma te koiora, ko te tikanga ko te maimoatanga ma te tango pokanga. Ka taea tenei ma te tangohanga ngawari mena he iti te mate pukupuku; Mena karekau te mate pukupuku i te iti, ko te nuinga o te waa ka tūtohu kia pokai Mohs.
Ko te mate pukupuku pūtau basal e 32% o nga mate pukupuku katoa o te ao. O nga mate pukupuku kiri i tua atu i te melanoma, tata ki te 80% he mate pukupuku kiri-waa. I roto i te United States, tata ki te 35% o nga tane ma me te 25% o nga wahine ma e pangia ana e te mate pukupuku o te tinana i etahi wa o to ratau oranga.
○ Taatari me te Maimoatanga
#Dermoscopy
#Skin biopsy
#Mohs surgery